bims-exocan Biomed News
on Exosomes roles in cancer
Issue of 2026–04–05
seven papers selected by
Muhammad Rizwan, COMSATS University



  1. Mol Diagn Ther. 2026 Mar 28.
      Exosomes are small extracellular vesicles secreted by various cells. They play a vital role in intercellular communication due to their diverse molecular cargo. Recent advancements in biomedical research have enabled a more detailed characterization of exosomes and their significant role in cancer biology, particularly in understanding mechanisms that contribute to chemoresistance. This review focuses on the current understanding of exosomes in ovarian cancer, one of the deadliest gynecological malignancies, known for its high recurrence and treatment failure rates. Chemoresistance in ovarian cancer stems from several factors, including altered drug efflux, enhanced DNA repair mechanisms, changes in the tumor microenvironment, and modifications in signaling pathways. Emerging evidence suggests that exosomes facilitate these processes by transferring regulatory molecules such as proteins, microRNAs (miRNAs), and circular RNAs (circRNAs) between cells, which in turn modulate drug response and tumor progression. For instance, exosomal proteins such as DNA methyltransferase 1 (DNMT1) and circular forkhead box P1 (circFoxp1), along with miRNAs like miR-21-3p, miR-1246, and miR-6836, have been associated with promoting resistance to platinum- and taxane-based chemotherapies. Conversely, some exosomal miRNAs, including miR-30a-5p, may enhance drug sensitivity. Furthermore, circRNAs transported by exosomes, such as hsa_circ_0010467, circ-PIP5K1A, and circ_0025033, play a role in regulating key oncogenic pathways associated with chemoresistance. Overall, these findings highlight the multifaceted role of exosomes in ovarian cancer biology and underscore their potential as both biomarkers and therapeutic targets. A deeper understanding of how exosomes mediate molecular mechanisms may lead to novel strategies for overcoming chemoresistance and improving treatment outcomes for ovarian cancer patients.
    DOI:  https://doi.org/10.1007/s40291-026-00844-7
  2. Clin Chim Acta. 2026 Mar 31. pii: S0009-8981(26)00171-3. [Epub ahead of print] 120989
      Small extracellular vesicles (sEVs) represent a novel frontier in oncology, functioning as critical mediators of intercellular communication that profoundly influence the biology of breast cancer. These nano-sized particles, typically ranging from 30 to 200 nm in diameter, are released by virtually all cell types into the extracellular space and circulate in biofluids like blood, urine, and saliva. Encased within a lipid bilayer, sEVs carry a complex molecular payload including proteins, lipids, various nucleic acids like microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), and metabolites that reflects the physiological or pathological state of their parent cell. In the context of breast cancer, these vesicles are not merely cellular debris but are active participants in orchestrating tumor progression, shaping the tumor microenvironment (TME), facilitating metastasis, and mediating resistance to therapies. This dual nature positions sEVs at the heart of precision medicine, offering immense potential as minimally invasive "liquid biopsies" for real-time diagnosis, prognosis, and treatment monitoring, while simultaneously presenting themselves as powerful tools for targeted therapeutic intervention. This review provides a comprehensive investigation into the multifaceted roles of sEVs in breast cancer, examining their applications as biomarkers and therapeutic targets across all major subtypes, integrating insights on underlying biological mechanisms, and critically evaluating their path toward clinical translation.
    Keywords:  Biomarkers; Breast cancer; Small extracellular vesicles; Therapeutic targeting; Tumor microenvironment
    DOI:  https://doi.org/10.1016/j.cca.2026.120989
  3. Discov Nano. 2026 Mar 29. pii: 87. [Epub ahead of print]21(1):
      Gliomas mainly glioblastoma multiforme (GBM) are the greatest lethal primary brain tumors, marked by rapid progression, high heterogeneity, and poor therapeutic outcomes. A main challenge in treating gliomas lies in the limited permeability of the blood-brain barrier (BBB), which restricts drug access to the tumor site. Conventional treatment protocols, including surgery, radiotherapy, and the Stupp regimen, offer only modest survival aids due to drug resistance and inefficient delivery. Recently, nanotechnology-based approaches have gained attention for enhancing drug transport across the BBB. Among them, exosomes endogenous extracellular vesicles have emerged as promising nanocarriers due to their innate biocompatibility, low immunogenicity, and natural ability to cross the BBB. These vesicles can be planned to deliver therapeutic agents selectively to tumor cells and modulate the tumor microenvironment (TME), influencing processes as well as angiogenesis, immune evasion, and intercellular signaling. This review articulates the innovative contributions of exosome-based drug delivery systems in glioma management, highlighting recent advancements in bioengineering approaches and their dual role in treatment and diagnostics (theranostics). By speaking the biological barriers to drug delivery and enhancing targeted therapeutic effects, exosomes represent a significant leap forward in precision medicine for glioma therapy. Additional clinical and translational research is crucial to fully realize the potential of exosomes as effective delivery systems in glioma treatment.
    Keywords:  Drug delivery; Exosome; Glioma treatment; Nanocarriers
    DOI:  https://doi.org/10.1186/s11671-026-04533-6
  4. Head Neck. 2026 Apr 03.
       BACKGROUND: Tumor cells adapt to hypoxia by releasing hiTDExs enriched with bioactive molecules that modulate endothelial behavior and promote tumor progression. This study aimed to characterize how hypoxia-induced HNSCC exosomes reshape the endothelial secretome and contribute to metastatic potential.
    METHODS: We examined whether hiTDExs reprogram endothelial cells and alter their secretome using cytokine arrays. Functional assays (migration, invasion, tube formation) showed a tumor-promoting role of CCL26 and tumor-suppressive effects of genetic inhibition of its receptor CCR3, while in silico and immunohistochemistry analyses assessed CCL26, HIF1A, and CD31 expression in relation to metastasis.
    RESULTS: Hypoxic exosomes from Detroit-562 and FaDu cells altered 25 and 52 proteins in HUVEC secretomes, with elevated CCL26 confirmed by ELISA. CCL26 significantly enhanced HNSCC cell proliferation, migration, and invasion, whereas CCL26 neutralization or genetic inhibition of its receptor CCR3 effectively abrogated these effects. High CCL26 and HIF1A correlated with metastasis, advanced stage, and poor survival.
    CONCLUSION: hiTDExs reprogram endothelial secretomes by elevating CCL26, promoting tumor-supportive phenotypes and driving metastatic progression in HNSCC.
    Keywords:  CCL26; chemokine; exosomes; head and neck carcinoma; hypoxia; secretome; tumor microenvironment
    DOI:  https://doi.org/10.1002/hed.70259
  5. Adv Clin Chem. 2026 ;pii: S0065-2423(26)00001-6. [Epub ahead of print]132 193-222
      Hepatocellular carcinoma (HCC), a prevalent malignant tumor, is characterized by occult early symptoms, leading to most patients being diagnosed at advanced stages. This diagnostic delay significantly contributes to the high mortality and limited therapeutic efficacy observed in HCC. Therefore, the development and application of accurate early detection methods and efficacious treatment strategies are essential for improving patient survival and overall clinical outcomes. Glycoproteomics focuses on the characterization of glycosylation sites and site-specific glycans. As one of the most prevalent post-translational modifications of proteins, aberrant glycosylation plays a critical role in the initiation, progression, diagnosis and treatment of HCC. In-depth investigation of abnormal glycoproteins in HCC holds substantial scientific and clinical significance for unraveling its pathogenesis, identifying effective diagnostic biomarkers, and pinpointing potential therapeutic targets. Body fluids and the derived exosomes have emerged as a pivotal research frontier, owing to their distinctive advantages: non-invasiveness, a wealth of disease-associated information, and ease of collection. Based on this, this review elaborates on the research strategies of HCC glycoproteomics and provides a detailed description of the analysis of body fluids and derived exosomes, to explore potential biomarkers in the pathogenesis of HCC, thereby providing strong support for the early detection and personalized treatment.
    Keywords:  Biomarker; Body fluids; Exosomes; Glycosylation; Hepatocellular carcinoma; Mass spectrometry; Proteomics
    DOI:  https://doi.org/10.1016/bs.acc.2026.01.001
  6. Biomed Pharmacother. 2026 Mar 27. pii: S0753-3322(26)00301-X. [Epub ahead of print]198 119268
      Hepatocellular carcinoma (HCC) employs multiple layers of immune evasion, among which exosomal programmed death-ligand 1 (exoPD-L1) has emerged as a key mediator and clinically relevant biomarker. Through vesicular packaging and systemic dissemination, exoPD-L1 reinforces an immunosuppressive milieu beyond the spatial constraints of membrane-bound PD-L1, thereby attenuating cytotoxic lymphocyte activity and facilitating tumor progression. Increasing evidence indicates that circulating exoPD-L1 constitutes a minimally invasive, dynamic biomarker that captures real-time immunological states, with potential utility in predicting responsiveness to immune checkpoint inhibitors, monitoring therapeutic trajectories, and refining patient stratification. Moreover, the biogenesis and functional deployment of exoPD-L1 reveal actionable vulnerabilities-ranging from neutralization and inhibition of vesicular loading to disruption of secretion pathways-that may augment current immunotherapeutic strategies in HCC. Nonetheless, methodological inconsistencies, heterogeneous assay platforms, and limited prospective validation currently constrain clinical translation. This review synthesizes mechanistic insights, evaluates liquid biopsy applications, and outlines emerging therapeutic interventions targeting the exoPD-L1 axis, highlighting priorities for future investigation.
    Keywords:  Biomarker; Exosomes; Hepatocellular carcinoma; Immune evasion; Immunotherapy; PD-L1
    DOI:  https://doi.org/10.1016/j.biopha.2026.119268
  7. Front Cell Dev Biol. 2026 ;14 1793573
      Extracellular vesicles (EVs) have emerged as vital mediators of intercellular communication, playing crucial roles in the initiation, progression, and metastasis of urogenital cancers. Due to their ability to carry diverse biological molecules and their excellent biocompatibility, EVs have garnered significant attention as novel tools for the diagnosis and treatment of malignancies such as prostate, bladder, kidney, and testicular cancers. This review summarizes recent progress in understanding the biological functions of EVs in various urogenital tumors, integrates findings from both fundamental studies and clinical trials, and discusses ongoing obstacles and future prospects in the field. By providing insights into the diagnostic and therapeutic applications of EVs, this article aims to support the development of precision medicine strategies for urogenital cancer patients.
    Keywords:  biomarkers; diagnosis; extracellular vesicles; treatment; urogenital cancers
    DOI:  https://doi.org/10.3389/fcell.2026.1793573